The antiphospholipid syndrome (APS) was reported in the early 1980s as a triad of manifestations. Since than it became one of the most systemic conditions. Almost any organ and tissue may be involved in the disease, including the brain, the heart, the placenta, the endocrine system, the blood, the kidneys and many more. In the article it is suggested to add to the syndrome the word systemic in analogy to its sister condition, systemic lupus erythematosus.
Hughes GRV.Thrombosis, abortion, cerebral disease and lupus anticoagulant . Br Med J1983; 187: 1088-1089 .
2.
Asherson RA , Khamashta MA , Ordi-Ros Jet al.The ‘primary’ antiphospholipid syndrome: major clinical and serological features . Medicine (Baltimore)1989; 68: 366-374 .
3.
Blank M , Cohen J , Toder V , Shoenfeld Y.Induction of anti-phospholipid syndrome by passive transfer of anti-cardiolipin antibodies . Proc Natl Acad Sci1991; 88: 3069-3073 .
4.
Bakimer R , Fishman P , Blank M , Sredni B , Djaldetti M , Shoenfeld Y.Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anti-cardiolipin antibody (H-3) . J Clin Invest1992; 89: 1558-1663 .
5.
Fishman P , Bakimer R , Blank M , Sredni D , Djaldetti M , Shoenfeld Y.The putative role of cytokines in the induction of primary anti-phospholipid syndrome . Clin Exp Immunol1992; 90: 266-270 .
6.
Blank M , Tincani A , Shoenfeld Y.Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies . J Rheumatol1994; 21: 100-104 .
7.
Kronenberg A , Blank M , Kaufman S , Shoenfeld Y.Induction of tissue factor like activity in monocytes by anti-cardiolipin antibodies . J Immunol1994; 153: 1328-1332 .
8.
Blank M , Faden D , Tincani Aet al.Immunization with anticardiolipin cofactor (β2 GP-I) induces experimental antiphospholipid syndrome in naive mice . J Autoimmun1994; 7: 441-455 .
9.
Shurtz-Swirsky R , Inbar O , Blank Met al.In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental hCG secretion during early pregnancy . Am J Reprod Immunol1993; 29: 206-210 .
10.
Inbar O , Blank M , Faden D , Tincani A , Lorber M , Shoenfeld Y.Prevention of fetal loss in experimental antiphospholipid syndrome by low molecular weight heparin . Am J Obstet Gynecol1993; 169: 423-426 .
11.
Krause I , Blank M , Gilburd B , Shoenfeld Y.The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome . Am J Reprod Immunol1993; 29: 155-161 .
12.
Fishman P , Falach-Vaknine E , Zigelman Ret al.Prevention of fetal-loss in experimental anti-phospholipid syndrome by in vivo administration of recombinant interleukin-3 . J Clin Invest1993; 91: 1834-1837 .
13.
Shoenfeld Y , Blank M.Effect of long acting thromboxane receptor antagonist (BMS 180,291)on experimental antiphospholipidsyndrome . Lupus1994; 3: 397-400 .
14.
Blank M , Krause AI , Fridkin Met al.Bacterial induction of autoantibodies to b2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome . J Clin Invest2002; 109: 797-804 .
15.
Blank M , Shoenfeld Y , Cabilly S , Heldman Y , Fridkin M , Katchalski-Katzir E.Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides . Proc Natl Acad Sci USA1999; 96: 5164-5168 .
16.
Sherer Y , Shoenfeld Y.Antiphospholipid antibodies in human and murine atherosclerosis. In: Asherson RA , Cervera R , Piette JC , Shoenfeld Y (eds). The antiphospholipid syndrome II, Elsevier: Amsterdam , 2002, pp 137-141.
17.
Asherson RA , Cervera R , Piette JC , Shoenfeld Y (eds). The antiphospholipid syndrome. CRC Press, Boca Raton, FL , 2000.
18.
Khamashta M. A. (ed.) Hughes syndrome-antiphospholipid Syndrome. Springer: London , 2000, pp 1-474.
19.
Asherson RA , Cervera R , Piette JC , Shoenfeled Y (eds). The antiphospholipid syndrome II, autoimmune thrombosis. Elsevier: Amsterdam , 2002, pp 1-457.
20.
Mujic F , Cuadrado MJ , Lepyd Met al.Primary APS evolving into SLE . J Rheumatol1955; 22: 1589-1592 .
21.
Khamashta MA , Quadrado MJ , Mujic F , Taub NA , Hunt BJ , Hughes GR.The management of thrombosis in the antiphospholipid-antibody syndrome . New Engl J Med1995; 332(15): 993-997 .
